Sorana Segal-Maurer, MD

Division of Infectious Diseases, New York–Presbyterian Queens
Flushing, New York, United States

Disclosure(s): Gilead Sciences, Inc.: Advisor/Consultant, Grant/Research Support, Honoraria; Janssen: Advisor/Consultant; Theratechnologies: Advisor/Consultant; ViiV: Advisor/Consultant

Presentation(s):

• 155 - Long-Acting Subcutaneous Lenacapavir in People with Multi-Drug Resistant HIV-1: 3-Year Results of the CAPELLA Study

  Thursday, October 17, 2024
  2:00 PM – 2:15 PM US PT